We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Koninklijke Philips NV | NYSE:PHG | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.11 | -0.41% | 26.71 | 26.88 | 26.63 | 26.88 | 350,717 | 15:34:16 |
From May 2019 to May 2024
By Razak Musah Baba
LONDON--Royal Philips NV (PHIA.AE) has received U.S. Food and Drug Administration clearance to market its Philips BlueControl, a wearable light therapy device to treat mild psoriasis at home.
The Dutch health-technology company obtained Europe's CE marking for the device in 2015 and has been selling it in European countries such as Germany and the U.K.
Following the FDA clearance, Philips said it would start talking with dermatologists and patient support groups in the U.S. and prepare for the commercial launch of BlueControl there in early 2018.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
(END) Dow Jones Newswires
July 13, 2017 09:47 ET (13:47 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Koninklijke Philips NV Chart |
1 Month Koninklijke Philips NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
